Rx Naloxone Marketer's OTC Switch Proposal For Nasal Spray Gets Priority Review From FDA

Emergent BioSolutions’ announcement of FDA accepting sNDA for an OTC 4-mg naloxone nasal spray marks another recent step in agency’s response under Commissioner Califf to Capitol Hill pressure to expand availability of topioid antagonist to help curb opioid overdose death epidemic.

With priority review granted for Emergent's sNDA for OTC Narcan nasal spay. FDA’s deadline under PDUFA for a decision is 29 March. • Source: Shutterstock

The US Food and Drug Administration is on the clock for a decision on an application for OTC naloxone before April 2023 after designating for priority review a proposal submitted by the marketer of Narcan, the Rx brand synonymous with the opioid overdose treatment.

Emergent BioSolutions, Inc.’s announcement on 6 December that the FDA had accepted its supplemental new drug application for an...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from Rx-to-OTC Switch

More from Health